HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
27 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
DDB2
damage specific DNA binding protein 2
Chromosome 11 Β· 11p11.2
NCBI Gene: 1643Ensembl: ENSG00000134574.13HGNC: HGNC:2718UniProt: Q92466
205PubMed Papers
21Diseases
0Drugs
15Pathogenic Variants
FUNCTIONAL ROLE
DNA RepairHub Gene
RESEARCH IMPACT
Trending
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
damaged DNA bindingubiquitin-protein transferase activityUV-damage excision repairnucleusxeroderma pigmentosum group EXeroderma pigmentosum complementation group Exeroderma pigmentosumprostate carcinoma
✦AI Summary

DDB2 (damage-specific DNA binding protein 2) is a DNA damage recognition factor that facilitates global genomic nucleotide excision repair (GG-NER), particularly in response to UV-induced DNA lesions 1. As a component of the DDB complex, DDB2 localizes to damaged DNA sites and functions within Cul4-RING E3 ubiquitin ligase complexes to promote repair through ubiquitin-mediated proteolysis 2. Mechanistically, DDB2 coordinates nucleotide excision repair in chr11 through multiple cellular regulatory levels, including nuclear translocation and transcriptional induction 2. Mutations in DDB2 cause xeroderma pigmentosum complementation group E (XP-E), characterized by extreme UV sensitivity and skin cancer predisposition 2. DDB2 functions as a tumor suppressor by controlling p53-mediated apoptosis after UV exposure; DDB2-deficient mice exhibit enhanced UV-induced skin carcinogenesis and resistance to UV-induced cell death 3. Beyond DNA repair, DDB2 regulates chr11 remodeling, gene transcription, and cell cycle control 1. DDB2 also suppresses HIF1Ξ± expression in hypoxic tumors, reducing angiogenic responses 4. In cancer cells, KRAS mutations enhance platinum chemotherapy resistance by stabilizing DDB2 mRNA through m6A methylation, thereby increasing DNA repair capacity 5.

Sources cited
1
DDB2 facilitates global genomic nucleotide excision repair and contributes to chromatin remodeling, gene transcription, cell cycle regulation, and cancer development
PMID: 31635251
2
Mutations in DDB2 are found in all confirmed cases of xeroderma pigmentosum group E; DDB2 functions within ubiquitin-mediated proteolysis complexes and assists in nucleotide excision repair in chromatin
PMID: 12967661
3
DDB2 functions as a tumor suppressor by controlling p53-mediated apoptosis after UV-irradiation; DDB2-deficient mice show enhanced skin carcinogenesis and resistance to UV-induced cell death
PMID: 14769931
4
DDB2 is upregulated by hypoxia and inhibits HIF1Ξ± expression by reducing mRNA expression and recruiting histone methyltransferases
PMID: 31740787
5
KRAS mutants stabilize DDB2 mRNA through m6A methylation, enhancing nucleotide excision repair and conferring platinum chemotherapy resistance in lung cancer
PMID: 39960727
Disease Associationsβ“˜21
xeroderma pigmentosum group EOpen Targets
0.75Strong
Xeroderma pigmentosum complementation group EOpen Targets
0.71Strong
xeroderma pigmentosumOpen Targets
0.48Moderate
hemangioblastomaOpen Targets
0.37Weak
Ovarian Endometrioid Adenocarcinoma with Squamous DifferentiationOpen Targets
0.37Weak
prostate carcinomaOpen Targets
0.37Weak
skin basal cell carcinomaOpen Targets
0.37Weak
cardiomyopathyOpen Targets
0.34Weak
mood disorderOpen Targets
0.33Weak
major depressive disorderOpen Targets
0.33Weak
acute myeloid leukemiaOpen Targets
0.33Weak
head and neck squamous cell carcinomaOpen Targets
0.31Weak
melanomaOpen Targets
0.30Weak
breast carcinomaOpen Targets
0.29Weak
non-small cell lung carcinomaOpen Targets
0.29Weak
lung adenocarcinomaOpen Targets
0.29Weak
lung carcinomaOpen Targets
0.29Weak
gastric adenocarcinomaOpen Targets
0.28Weak
hepatocellular carcinomaOpen Targets
0.28Weak
pancreatic ductal adenocarcinomaOpen Targets
0.28Weak
Xeroderma pigmentosum complementation group EUniProt
Pathogenic Variants15
NM_000107.3(DDB2):c.1063C>T (p.Arg355Ter)Pathogenic
not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 355
NM_000107.3(DDB2):c.818G>A (p.Arg273His)Pathogenic
Xeroderma pigmentosum, group E|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 273
NM_000107.3(DDB2):c.85dup (p.Glu29fs)Likely pathogenic
Xeroderma pigmentosum, group E
β˜…β˜…β˜†β˜†2024β†’ Residue 29
NM_000107.3(DDB2):c.730_733del (p.Lys243_Lys244insTer)Pathogenic
not provided|Xeroderma pigmentosum, group E
β˜…β˜…β˜†β˜†2020β†’ Residue 243
NM_000107.3(DDB2):c.880+1G>TLikely pathogenic
Xeroderma pigmentosum, group E
β˜…β˜†β˜†β˜†2024
NM_000107.3(DDB2):c.702+1G>TPathogenic
not provided
β˜…β˜†β˜†β˜†2024
NM_000107.3(DDB2):c.970dup (p.Leu324fs)Likely pathogenic
Xeroderma pigmentosum, group E
β˜…β˜†β˜†β˜†2024β†’ Residue 324
NM_000107.3(DDB2):c.456+2T>CLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2022
NM_000107.3(DDB2):c.1187C>A (p.Ser396Ter)Pathogenic
Xeroderma pigmentosum, group E
β˜…β˜†β˜†β˜†2022β†’ Residue 396
NM_000107.3(DDB2):c.574C>T (p.Arg192Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2021β†’ Residue 192
NM_000107.3(DDB2):c.937C>T (p.Arg313Ter)Pathogenic
Xeroderma pigmentosum, group E
β˜…β˜†β˜†β˜†2021β†’ Residue 313
NM_000107.3(DDB2):c.457-2A>CLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2019
NM_000107.3(DDB2):c.640C>T (p.Arg214Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2017β†’ Residue 214
NM_000107.3(DDB2):c.919G>T (p.Asp307Tyr)Pathogenic
Xeroderma pigmentosum, group E
β˜†β˜†β˜†β˜†2003β†’ Residue 307
NM_000107.3(DDB2):c.730A>G (p.Lys244Glu)Pathogenic
Xeroderma pigmentosum, group E
β˜†β˜†β˜†β˜†1999β†’ Residue 244
View on ClinVar β†—
Related Genes
CDKN1BProtein interaction100%CUL4AProtein interaction100%DCAF1Protein interaction100%DET1Protein interaction100%CRBNProtein interaction100%H2AC8Protein interaction100%
Tissue Expression6 tissues
Liver
100%
Lung
96%
Bone Marrow
82%
Ovary
75%
Heart
45%
Brain
30%
Gene Interaction Network
Click a node to explore
DDB2CDKN1BCUL4ADCAF1DET1CRBNH2AC8
PROTEIN STRUCTURE
Preparing viewer…
PDB3I7L Β· 2.80 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.72LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.53 [0.39–0.72]
RankingsWhere DDB2 stands among ~20K protein-coding genes
  • #2,039of 20,598
    Most Researched205 Β· top 10%
  • #2,439of 5,498
    Most Pathogenic Variants15
  • #5,534of 17,882
    Most Constrained (LOEUF)0.72
Genes detectedDDB2
Sources retrieved27 papers
Response timeβ€”
πŸ“„ Sources
27β–Ό
1
DDB complexities.
PMID: 12967661
DNA Repair (Amst) Β· 2003
1.00
2
Emerging Roles of DDB2 in Cancer.
PMID: 31635251
Int J Mol Sci Β· 2019
0.90
3
KRAS mutants confer platinum resistance by regulating ALKBH5 posttranslational modifications in lung cancer.
PMID: 39960727
J Clin Invest Β· 2025
0.80
4
Damaged DNA-binding protein 2 (DDB2) protects against UV irradiation in human cells and Drosophila.
PMID: 20398405
J Biomed Sci Β· 2010
0.76
5
BAX and DDB2 as biomarkers for acute radiation exposure in the human blood ex vivo and non-human primate models.
PMID: 39164366
Sci Rep Β· 2024
0.72